Featured Videos #1 – BJC TV https://tv.bjcardio.co.uk Short video updates for cardiologists Fri, 07 Aug 2026 15:52:06 +0000 en-GB hourly 1 https://wordpress.org/?v=7.0.3 https://tv.bjcardio.co.uk/wp-content/uploads/2023/06/cropped-favicon-32x32.png Featured Videos #1 – BJC TV https://tv.bjcardio.co.uk 32 32 BEACON series – Episode 1: Primary prevention of CVD – QRISK® <10% https://tv.bjcardio.co.uk/cardiovascular-medicine/beacon-series-episode-1-primary-prevention-of-cvd-qrisk-10/ Fri, 07 Aug 2026 08:12:00 +0000 https://tv.bjcardio.co.uk/?p=11855 Faculty

Chair
Professor Mike Cummings, Consultant Endocrinologist, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust

Speakers
Beverley Bostock, Advanced Nurse Practitioner, Mann Cottage Surgery, Gloucestershire
Dr Paul Downie, Consultant Chemical Pathologist, University Hospitals Bristol and Weston NHS Trust, Bristol
Dr Jim Moore, General Practitioner, Gloucestershire Care Services NHS Trust, Brockworth
Emily Turner, General Practice Pharmacist, Aire Valley Surgery and Guiseley and Yeadon Medical Practice, Leeds

Abbreviations

BEACON, Bringing Education and Awareness to Cholesterol Optimisation Needs; CVD, cardiovascular disease.

]]> Heart failure in black patients – exploring genes and cardiac amyloidosis https://tv.bjcardio.co.uk/cardiovascular-medicine/heart-failure-in-black-patients-exploring-genes-and-cardiac-amyloidosis/ Wed, 22 Jul 2026 16:12:45 +0000 https://tv.bjcardio.co.uk/?p=11908

Learning objectives:

  • To understand the difference between Transthyretin Amyloidosis (ATTR) and Amyloid Light-chain Amyloidosis (AL)
  • To learn about the hereditary subtype ATTR V122I and how it affects patients of black ethnicity
  • To develop an understanding of the challenges faced in diagnosing and treating this condition
  • To gain awareness of ways to support black patients with hereditary ATTR and those who carry the gene
  • To feel empowered to diagnose ATTR and develop a knowledge of the condition to implement in clinical practise in a culturally sensitive way.

 

Speaker

Dr Jason Dungu PhD, FRCP, FESC

Consultant Cardiologist and Essex ICC Lead, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust Honorary Senior Clinical Lecturer, Anglia Ruskin University 

]]> Key differences between Kerendia▼ (finerenone) and steroidal MRAs https://tv.bjcardio.co.uk/cardiovascular-medicine/key-differences-between-kerendia-and-steroidal-mras/ Fri, 19 Jun 2026 14:01:00 +0000 https://tv.bjcardio.co.uk/?p=11756 1–4]]> Prescribing information and adverse event reporting information for Kerendia®▼(finerenone) can be found here.

Featuring

Professor John McMurray, Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health
Professor Richard Hobbs, Mercian Professor of Primary Care, University of Oxford

References
  1. Piccirillo F, Liporace P, Nusca A et al. Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality‑a comprehensive review. J Cardiovasc Dev Dis 2023;10:236.
  2. Kolkhof P, Jaisser F, Kim S-Y et al. Steroidal and novel non‑steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. In Bauersachs J et al (eds): Heart failure. Springer International Publishing, Cham, Switzerland, 2017:271–305.
  3. Spironolactone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/12015/smpc#gref.
  4. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8810/smpc.

DOWNLOAD OUR DOSING GUIDE

]]> Exercise in cardiomyopathy: What happens after the consultation? https://tv.bjcardio.co.uk/cardiovascular-medicine/exercise-in-cardiomyopathy-what-happens-after-the-consultation/ Fri, 29 May 2026 10:18:16 +0000 https://tv.bjcardio.co.uk/?p=11778

Learning objectives: 

  • To understand that exercise is possible for nearly all cardiomyopathy patients
  • To learn successful ways to tailor exercise for individual patients  
  • To develop an understanding of the ACTIVE clinical approach and the four pillars of cardiovascular rehabilitation
  • To gain awareness of how to support patients safely with practical exercise prescription  
  • To feel inspired to help patients manage their cardiovascular health with confidence  

 

Speaker: Shane Purcell Clinical Exercise Physiologist, Imperial College Healthcare NHS Trust

 

]]> Insights from the ESC Heart Failure Congress, 2026 https://tv.bjcardio.co.uk/cardiovascular-medicine/insights-from-the-esc-heart-failure-congress-2026/ Fri, 15 May 2026 14:02:25 +0000 https://tv.bjcardio.co.uk/?p=11734

Learn more about some of the key sessions from the conference:

Cardiac amyloidosis: early diagnosis matters

Controversies in contemporary drug therapy for heart failure

How to crack the cardiorenal code: from clinical mastery to unit creation

Advances in cardiomyopathies

Debate: artificial intelligence in heart failure care, a great equaliser or a new divider?

Speaker

Dr Sarah Birkhoelzer, Heart Failure and Imaging Fellow, University Hospital Dorset

 

]]> Living and dying well with heart failure – how can palliative care help? https://tv.bjcardio.co.uk/cardiovascular-medicine/living-and-dying-well-with-heart-failure-how-can-palliative-care-help/ Wed, 06 May 2026 09:35:23 +0000 https://tv.bjcardio.co.uk/?p=11670 Learning objectives:

  • To understand the potential role of palliative care in supporting heart failure patients
  • To learn about down titrating some medications to improve symptom control and reduce side effects 
  • To develop an understanding of advance care planning including DNACPR & ICD deactivation
  • To gain awareness of the ethical dilemmas that might arise
  • To feel inspired to develop relationships with your local palliative care providers and work together more closely

Speaker

Dr Sharon Chadwick, Consultant in Palliative Medicine, Hospice of St Francis, Berkhamsted, Hertfordshire

]]> What to expect when you visit the National Amyloidosis Centre https://tv.bjcardio.co.uk/featured-videos-1/what-to-expect-when-you-visit-the-national-amyloidosis-centre/ Thu, 23 Apr 2026 10:30:25 +0000 https://tv.bjcardio.co.uk/?p=11692 Key takeaways:
  • Early detection and accurate diagnosis are essential for optimising clinical management and improving outcomes in patients with amyloidosis
  • The National Amyloidosis Centre has a range of advanced diagnostic techniques to confirm the presence of amyloidosis in a person
  • Investigations may include SAP scintigraphy, cardiac MRI scans, DPD scans and genetic testing
  • Accurate subtyping enables tailored therapeutic strategies, which are key to effective disease management
Speakers

Emily Dixon, Principal Genetic Counsellor
Darren Foard, Lead AL Amyloidosis Clinical Nurse Specialist
Professor Philip Hawkins, Consultant Physician; Clinical Director; Founder of NAC
David Hutt, Lead Nuclear Medicine Technologist
Dr Ana Martinez Naharro, Consultant Cardiologist
Dr Tamer Rezk, Consultant Nephrologist
Dr Dorota Rowczenio, Head of Genetic Service
Angelique Smit, Lead Clinical and Research Nurse

]]> The National Amyloidosis Centre: A guide for clinicians https://tv.bjcardio.co.uk/featured-videos/the-national-amyloidosis-centre-a-guide-for-clinicians/ Thu, 23 Apr 2026 10:25:36 +0000 https://tv.bjcardio.co.uk/?p=11683 Key takeaways:
  • Early detection and diagnosis are key for improving outcomes in people with amyloidosis
  • There are 3 major types of amyloidosis seen at the NAC, each requiring specialised treatment
  • The NAC processes over 2500 cases of amyloidosis per year and offers a holistic approach to managing amyloidosis, including genetic counselling
Speakers

Christine Chiti, Clinical TTR Nurse Specialist
Emily Dixon, Principal Genetic Counsellor
Professor Marianna Fontana, Deputy Clinical and Research Lead
Janet Gilbertson, Head of Histology; Proteomic Service and Laboratory Manager
Professor Julian Gillmore, NAC Research Lead
Professor Philip Hawkins, Consultant Physician; Clinical Director; Founder of NAC
Dr Yousuf Razvi, Clinical Research Fellow
Angelique Smit, Lead Clinical and Research Nurse
Dr Tamer Rezk, Consultant Nephrologist
Professor Ashu Wechalekar, Laboratory Director and Consultant Haematologist
Dr Carol Whelan, Consultant Cardiologist

]]> The barriers to early diagnosis of cardiac amyloidosis in women https://tv.bjcardio.co.uk/featured-videos-1/the-barriers-to-early-diagnosis-of-cardiac-amyloidosis-in-women/ Tue, 31 Mar 2026 08:18:37 +0000 https://tv.bjcardio.co.uk/?p=11313 Speaker

Professor Marianna Fontana, Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, University College London

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and ATTR-CM, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Abbreviation:
ATTR-CM: Transthyretin amyloid cardiomyopathy.

PP-UNP-GBR-14079 | March 2026

]]> British Society of Echocardiography guideline for the TTE assessment of cardiac amyloidosis and the role of ECHO in monitoring disease progression in cardiac amyloidosis https://tv.bjcardio.co.uk/featured-videos-1/british-society-of-echocardiography-guideline-for-the-tte-assessment-of-cardiac-amyloidosis-and-the-role-of-echo-in-monitoring-disease-progression-in-cardiac-amyloidosis/ https://tv.bjcardio.co.uk/featured-videos-1/british-society-of-echocardiography-guideline-for-the-tte-assessment-of-cardiac-amyloidosis-and-the-role-of-echo-in-monitoring-disease-progression-in-cardiac-amyloidosis/#comments Tue, 31 Mar 2026 08:16:57 +0000 https://tv.bjcardio.co.uk/?p=11298 Speaker

Dr William E Moody, Consultant Cardiologist, Queen Elizabeth Hospital, Birmingham

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and transthyretin amyloid cardiomyopathy, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Reference

Moody, William E et al. “British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.” Echo research and practice vol. 10,1 13. 31 Aug. 2023, doi:10.1186/s44156-023-00028-7

Abbreviations:
ECHO: echocardiography; TTE: transthoracic echocardiography.

PP-UNP-GBR-14075 | March 2026

]]> https://tv.bjcardio.co.uk/featured-videos-1/british-society-of-echocardiography-guideline-for-the-tte-assessment-of-cardiac-amyloidosis-and-the-role-of-echo-in-monitoring-disease-progression-in-cardiac-amyloidosis/feed/ 1